Radiotherapy in Breast Cancer

Radiotherapy in breast cancer is one of the main local treatments used to reduce the risk of recurrence after surgery or, in selected situations, to support local disease control. Whether it is recommended depends on the type of surgery, tumour stage, lymph-node status, margins, and the overall treatment plan. ^[1][2][3][4]

In which patients does it become relevant?

In breast cancer, radiotherapy is often used after breast-conserving surgery because radiation to the remaining breast tissue lowers the chance of the cancer returning in that area. In some patients who undergo mastectomy, irradiation of the chest wall and sometimes regional lymph-node areas is also advised, especially when tumour size, nodal involvement, margin status, or other risk features suggest a meaningful recurrence risk. This is why the answer to “Does everyone need radiotherapy?” is no; the indication depends on the balance of expected benefit and treatment burden. ^[1][2][4][5]

The treatment may also be considered for symptom control in advanced disease, for example when pain, bleeding, or local progression needs palliative management. However, the most common use remains postoperative risk reduction. Decisions are increasingly individualised according to tumour biology, age, comorbidities, genomic information in selected settings, and whether systemic treatments such as chemotherapy, endocrine therapy, or anti-HER2 therapy are also planned. ^[1][3][4][6]

What do planning and treatment sessions look like?

Before treatment begins, patients usually undergo a planning or simulation appointment. During this session, the treatment position is set, planning images are obtained, and the team determines which areas require radiation and which nearby structures should be protected as much as possible. In breast radiotherapy, this often includes careful attention to the skin, lung, heart, and lymph-node regions. For left-sided tumours in particular, techniques such as deep-inspiration breath hold may help reduce cardiac exposure. ^[2][4][5][7]

Treatment is usually delivered over several sessions, though shorter schedules are now common in many patients. Some centres may recommend whole-breast irradiation, while others may consider partial-breast approaches in selected low-risk cases. Additional “boost” treatment to the tumour bed may be used depending on age, pathology, and recurrence risk. The exact schedule should always be understood in the context of the patient’s surgery, pathology report, and broader treatment sequence. ^[1][2][4][5]

What side effects can occur?

Most side effects are local and develop gradually. Skin redness, tenderness, dryness, swelling, fatigue, and a sense of heaviness in the breast or chest wall are among the common short-term effects. Many patients fear that the breast will be severely “burned,” but severe skin reactions are not inevitable and depend on dose, fractionation, skin characteristics, smoking status, and other treatment factors. Patients should still report worsening pain, moist skin breakdown, fever, marked swelling, or symptoms that interfere with eating, sleeping, or movement. ^[1][2][3][6]

Longer-term issues may include changes in breast texture or shape, fibrosis, persistent skin colour change, limited shoulder movement, or lymphoedema, especially when nodal areas are treated or axillary surgery has also been performed. Heart and lung exposure are carefully minimised during modern planning, but these organs still matter when the treatment field is close to them. That is why high-quality planning and follow-up are so important. ^[2][4][5][7]

Follow-up and daily life after treatment

Completing radiotherapy does not instantly end all treatment-related effects. Some symptoms continue to evolve for several weeks, and cosmetic outcome or tissue firmness may change over a longer period. Patients often need advice about skin care, activity, bra support, exercise, scar mobility, and early warning signs of lymphoedema. A structured follow-up plan also helps integrate radiotherapy with endocrine therapy, HER2-directed treatment, surveillance imaging, and return to work or daily responsibilities. ^[1][3][4][6]

Many people can continue part of their usual routine during treatment, but fatigue and travel for daily sessions may require adjustments. It is often helpful to think of breast radiotherapy not as an isolated step, but as one part of a broader survivorship pathway. Good preparation, realistic expectations, and quick reporting of side effects generally improve both tolerance and confidence. ^[2][4][7]

Which facts matter most when making the treatment decision?

The treatment decision is guided by pathology and risk, not by one-size-fits-all rules. Important factors include whether surgery conserved the breast, whether margins are clear, tumour size, nodal burden, biological subtype, age, comorbidities, reconstruction issues, and personal values about recurrence risk versus treatment burden. A patient who understands why radiotherapy is recommended—or why it may reasonably be omitted—is usually better positioned to make a meaningful shared decision. ^[1][2][5]